Literature DB >> 3101769

bcr-abl RNA in patients with chronic myelogenous leukemia.

E Shtivelman, R P Gale, O Dreazen, A Berrebi, R Zaizov, I Kubonishi, I Miyoshi, E Canaani.   

Abstract

The major consequence of the formation of the Philadelphia (Ph1) chromosome characteristic of leukemia cells of patients with chronic myelogenous leukemia (CML) is fusion of c-abl and bcr genes. Using a sensitive RNase protection technique, we analyzed mRNA from a large number of CML patients. In most, we identified one or both species of bcr-abl chimeric transcripts. These two mRNAs vary in the specific bcr exon joined to abl exon II and are translated into slightly different proteins. The amounts of the fused mRNA within leukemia cells vary considerably between individuals and do not correlate with the phase of the disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101769

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 2.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 3.  Molecular analysis of Philadelphia chromosome positive leukaemias.

Authors:  B D Young
Journal:  Br J Cancer Suppl       Date:  1988-12

4.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  p53 in chronic myelogenous leukemia in acute phase.

Authors:  E Feinstein; G Cimino; R P Gale; G Alimena; R Berthier; K Kishi; J Goldman; A Zaccaria; A Berrebi; E Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

6.  Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.

Authors:  J C Young; O N Witte
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

7.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

8.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.

Authors:  E S Kawasaki; S S Clark; M Y Coyne; S D Smith; R Champlin; O N Witte; F P McCormick
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.

Authors:  László Kereskai; János A Vass; Mária Kneif; László Pajor
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

10.  Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.

Authors:  A Grossman; R T Silver; Z Arlin; M Coleman; E Camposano; P Gascon; P A Benn
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.